ProKidney (PROK) Financials

$1.66 -0.05 (-2.92%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+1.08%)

As of 05/15/2026 07:56 PM Eastern

Annual Income Statements for ProKidney

This table shows ProKidney's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-27	-55	-108	-35	-61
Consolidated Net Income / (Loss)	-27	-55	-148	-135	-163
Net Income / (Loss) Continuing Operations	-27	-55	-148	-135	-163
Total Pre-Tax Income	-27	-55	-147	-129	-164
Total Operating Income	-27	-55	-153	-152	-184
Total Gross Profit	0.00	0.00	0.00	0.00	0.08
Total Revenue	0.00	0.00	0.00	0.00	0.08
Operating Revenue	-	-	0.00	0.00	0.08
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	27	55	153	152	184
Selling, General & Admin Expense	5.98	8.86	71	45	56
Research & Development Expense	21	46	82	107	128
Total Other Income / (Expense), net	0.04	0.00	5.77	22	20
Interest Expense	0.00	0.00	0.22	0.01	0.01
Interest & Investment Income	0.04	0.00	5.98	22	20
Income Tax Expense	-0.23	0.04	0.90	6.00	-0.60
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-40	-100	-102
Basic Earnings per Share	$0.00	$0.00	($0.23)	($0.57)	($0.62)
Weighted Average Basic Shares Outstanding	0.00	0.00	61.54M	61.71M	97.92M
Diluted Earnings per Share	$0.00	$0.00	($0.23)	($0.57)	($0.62)
Weighted Average Diluted Shares Outstanding	0.00	0.00	61.54M	61.71M	97.92M
Weighted Average Basic & Diluted Shares Outstanding	-	-	234.92M	229.34M	292.70M

This table shows ProKidney's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-64	-9.12	-11	49	-9.49	-13	-18	30	-17	-17	-16
Consolidated Net Income / (Loss)	-37	-35	-42	-22	-35	-38	-41	-48	-38	-37	-36
Net Income / (Loss) Continuing Operations	-37	-35	-42	-22	-35	-38	-41	-48	-38	-37	-36
Total Pre-Tax Income	-36	-34	-41	-19	-35	-39	-43	-47	-37	-36	-35
Total Operating Income	-41	-40	-47	-24	-40	-43	-49	-52	-41	-40	-39
Total Gross Profit	0.00	0.00	0.00	-	0.00	0.00	0.00	0.08	0.23	0.22	0.22
Total Revenue	0.00	0.00	0.00	-	0.00	0.00	0.00	0.08	0.23	0.22	0.22
Operating Revenue	-	-	-	-	0.00	0.00	0.00	-	0.23	0.22	0.22
Total Cost of Revenue	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Operating Expenses	41	40	47	24	40	43	49	52	42	40	39
Selling, General & Admin Expense	15	13	14	1.68	13	14	18	12	14	14	12
Research & Development Expense	26	26	32	23	27	29	31	40	27	26	27
Total Other Income / (Expense), net	5.29	5.96	5.54	5.28	4.84	4.53	5.58	4.79	4.03	3.59	3.26
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest & Investment Income	5.30	5.97	5.54	5.28	4.84	4.54	5.58	4.79	4.03	3.59	3.26
Income Tax Expense	1.33	0.97	0.91	2.79	0.10	-0.06	-2.34	1.70	0.59	0.85	0.56
Net Income / (Loss) Attributable to Noncontrolling Interest	27	-26	-31	-71	-26	-26	-23	-79	-21	-20	-19
Basic Earnings per Share	($0.16)	($0.14)	($0.18)	($0.09)	($0.16)	($0.16)	($0.14)	($0.16)	($0.13)	($0.13)	($0.12)
Weighted Average Basic Shares Outstanding	61.54M	64.56M	61.59M	61.71M	60.95M	75.91M	126.17M	97.92M	128.98M	130.73M	134.99M
Diluted Earnings per Share	($0.16)	($0.14)	($0.18)	($0.09)	($0.16)	($0.16)	($0.14)	($0.16)	($0.13)	($0.13)	($0.12)
Weighted Average Diluted Shares Outstanding	61.54M	64.56M	61.59M	61.71M	60.95M	75.91M	126.17M	97.92M	128.98M	130.73M	134.99M
Weighted Average Basic & Diluted Shares Outstanding	235.13M	235.25M	-	229.34M	231.70M	289.68M	291.66M	292.70M	292.70M	294.28M	300.83M

This table details how cash moves in and out of ProKidney's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-11	16	470	-430	38
Net Cash From Operating Activities	-25	-50	-77	-90	-126
Net Cash From Continuing Operating Activities	-25	-50	-77	-90	-126
Net Income / (Loss) Continuing Operations	-27	-55	-148	-135	-163
Consolidated Net Income / (Loss)	-27	-55	-148	-135	-163
Depreciation Expense	0.96	1.98	3.04	3.85	5.43
Non-Cash Adjustments To Reconcile Net Income	0.73	0.70	74	25	28
Changes in Operating Assets and Liabilities, net	-0.13	2.16	-6.46	17	3.96
Net Cash From Investing Activities	-5.46	-5.19	-1.74	-330	20
Net Cash From Continuing Investing Activities	-5.46	-5.19	-1.74	-330	20
Purchase of Property, Plant & Equipment	-5.46	-5.19	-1.85	-34	-30
Purchase of Investments	-	0.00	0.00	-472	-324
Divestitures	-	-	-	0.00	0.00
Sale and/or Maturity of Investments	-	0.00	0.00	176	374
Other Investing Activities, net	0.00	0.00	0.11	0.00	0.00
Net Cash From Financing Activities	20	71	549	-9.55	144
Net Cash From Continuing Financing Activities	20	71	549	-9.55	144
Repayment of Debt	0.00	0.00	-35	0.00	0.00
Repurchase of Common Equity	-	0.00	0.00	-9.50	0.00
Issuance of Debt	0.00	0.00	35	0.00	0.00
Issuance of Common Equity	0.00	0.00	0.00	0.00	144
Other Financing Activities, net	20	71	549	-0.05	0.09
Cash Income Taxes Paid	0.15	0.07	1.95	2.86	0.07

This table details how cash moves in and out of ProKidney's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025
Net Change in Cash & Equivalents	-219	-28	-52	-131	24	130	-106	-8.97	-1.32	-13	10
Net Cash From Operating Activities	-26	-15	-24	-25	-35	-38	-29	-24	-30	-31	-27
Net Cash From Continuing Operating Activities	-26	-15	-24	-25	-35	-38	-29	-24	-30	-31	-27
Net Income / (Loss) Continuing Operations	-37	-35	-42	-22	-35	-38	-41	-48	-38	-37	-36
Consolidated Net Income / (Loss)	-37	-35	-42	-22	-35	-38	-41	-48	-38	-37	-36
Depreciation Expense	0.83	0.87	1.01	1.15	1.10	1.27	1.49	1.57	1.60	1.47	1.67
Non-Cash Adjustments To Reconcile Net Income	13	9.71	11	-8.71	5.39	6.42	11	5.34	5.65	5.98	6.27
Changes in Operating Assets and Liabilities, net	-2.45	9.32	5.89	3.91	-5.81	-7.52	-0.27	18	1.11	-1.89	1.30
Net Cash From Investing Activities	-193	-13	-28	-96	58	29	-82	15	28	19	29
Net Cash From Continuing Investing Activities	-193	-13	-28	-96	58	29	-82	15	28	19	29
Purchase of Property, Plant & Equipment	-0.99	-3.70	-28	-1.57	-0.96	-0.64	-2.40	-26	-1.14	-3.11	-5.20
Purchase of Investments	-198	-64	-40	-170	-55	-27	-194	-47	-55	-43	-79
Sale and/or Maturity of Investments	6.41	54	39	76	115	57	115	87	85	64	113
Net Cash From Financing Activities	-0.01	-0.01	-0.01	-9.51	-0.01	140	4.46	0.12	-0.01	-0.01	7.96
Net Cash From Continuing Financing Activities	-0.01	-0.01	-0.01	-9.51	-0.01	140	4.46	0.12	-0.01	-0.01	7.96
Issuance of Common Equity	-	-	-	-	0.00	-	4.47	-0.00	0.00	-	7.10
Other Financing Activities, net	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	0.13	-0.01	-0.01	0.86

This table presents ProKidney's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	40	518	421	441
Total Current Assets	27	505	374	396
Cash & Equivalents	21	490	61	99
Short-Term Investments	-	0.00	302	259
Prepaid Expenses	6.69	13	9.81	16
Other Current Assets	0.03	1.38	1.38	22
Plant, Property, & Equipment, net	11	11	42	42
Total Noncurrent Assets	1.67	2.57	4.26	2.97
Intangible Assets	0.43	0.21	-	0.00
Other Noncurrent Operating Assets	1.24	2.36	4.26	2.97
Total Liabilities & Shareholders' Equity	40	518	421	441
Total Liabilities	13	13	29	39
Total Current Liabilities	12	11	25	36
Accounts Payable	2.83	3.04	5.10	3.63
Accrued Expenses	9.21	7.34	18	31
Current Deferred & Payable Income Tax Liabilities	-	0.00	1.47	0.68
Other Current Liabilities	0.27	0.49	0.80	0.77
Total Noncurrent Liabilities	1.07	2.18	4.18	3.22
Noncurrent Deferred Revenue	0.00	0.28	0.57	0.75
Other Noncurrent Operating Liabilities	1.07	1.91	3.61	2.47
Commitments & Contingencies	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	1,602	1,495	1,397
Total Equity & Noncontrolling Interests	27	-1,097	-1,103	-995
Total Preferred & Common Equity	27	-1,097	-1,103	-995
Total Common Equity	27	-1,097	-1,103	-995
Common Stock	188	7.50	36	206
Retained Earnings	-162	-1,104	-1,140	-1,201
Accumulated Other Comprehensive Income / (Loss)	-	0.00	0.13	0.13

This table presents ProKidney's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	532	495	484	388	499	475	406	372	352
Total Current Assets	519	480	466	340	450	430	360	324	300
Cash & Equivalents	506	272	244	84	215	108	98	85	95
Short-Term Investments	-	192	203	245	217	299	231	210	176
Prepaid Expenses	13	11	12	9.26	16	17	9.98	8.02	7.87
Other Current Assets	0.16	5.68	8.69	1.90	2.75	6.13	21	22	20
Plant, Property, & Equipment, net	11	12	15	42	43	39	43	44	48
Total Noncurrent Assets	2.37	3.20	2.99	5.67	6.33	6.05	3.07	4.17	3.87
Intangible Assets	0.27	0.16	0.11	0.00	0.00	0.00	0.00	0.00	0.00
Other Noncurrent Operating Assets	2.11	3.04	2.88	5.67	6.33	6.05	3.07	4.17	3.87
Total Liabilities & Shareholders' Equity	532	495	484	388	499	475	406	372	352
Total Liabilities	12	14	27	25	27	31	36	33	33
Total Current Liabilities	9.84	11	24	19	21	25	33	28	29
Accounts Payable	3.45	3.80	2.83	3.38	2.93	2.85	3.12	2.44	1.94
Accrued Expenses	5.96	6.85	21	13	15	21	28	25	26
Current Deferred & Payable Income Tax Liabilities	-	-	0.07	1.57	1.52	0.00	1.26	0.00	0.06
Other Current Liabilities	0.43	0.62	0.65	1.09	1.03	1.07	0.86	0.90	0.99
Total Noncurrent Liabilities	2.03	2.89	2.78	5.43	6.21	6.14	3.28	4.42	4.21
Capital Lease Obligations	1.72	-	-	4.86	-	-	2.51	-	3.25
Noncurrent Deferred Revenue	0.31	0.43	0.49	0.57	0.57	0.77	0.76	0.90	0.96
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	1,617	2,082	1,779	1,459	1,445	1,423	1,369	1,342	1,326
Total Equity & Noncontrolling Interests	-1,096	-1,602	-1,322	-1,096	-972	-980	-999	-1,003	-1,008
Total Preferred & Common Equity	-1,096	-1,602	-1,322	-1,096	-972	-980	-999	-1,003	-1,008
Total Common Equity	-1,096	-1,602	-1,322	-1,096	-972	-980	-999	-1,003	-1,008
Common Stock	1.48	22	31	53	189	200	219	232	243
Retained Earnings	-1,098	-1,623	-1,353	-1,149	-1,162	-1,180	-1,218	-1,234	-1,251
Accumulated Other Comprehensive Income / (Loss)	-	-0.02	-0.13	-0.04	-0.01	0.32	0.08	0.03	0.07

This table displays calculated financial ratios and metrics derived from ProKidney's official financial filings.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-103.86%	-182.29%	1.54%	-20.71%
EBIT Growth	0.00%	-103.93%	-177.64%	0.97%	-21.22%
NOPAT Growth	0.00%	-103.93%	-177.64%	0.97%	-21.22%
Net Income Growth	0.00%	-106.16%	-168.62%	8.57%	-20.59%
EPS Growth	0.00%	0.00%	0.00%	-147.83%	-8.77%
Operating Cash Flow Growth	0.00%	-99.75%	-53.26%	-16.84%	-40.28%
Free Cash Flow Firm Growth	0.00%	0.00%	-156.88%	-3.75%	-19.85%
Invested Capital Growth	0.00%	0.00%	130.96%	93.27%	52.70%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	4.14%	-17.80%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	3.82%	-17.50%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	3.82%	-17.50%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	2.06%	-19.59%
EPS Q/Q Growth	0.00%	0.00%	0.00%	1.72%	-12.73%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-3.73%	-11.96%	0.95%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	1.74%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	18.25%
Profitability Metrics	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	-234,531.58%
Operating Margin	0.00%	0.00%	0.00%	0.00%	-241,678.95%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	-241,678.95%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	-214,914.47%
Tax Burden Percent	99.14%	100.07%	100.61%	104.63%	99.64%
Interest Burden Percent	99.84%	100.00%	96.23%	85.43%	89.25%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-358.49%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-348.85%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	317.29%
Return on Equity (ROE)	0.00%	-204.87%	-55.70%	-30.22%	-41.20%
Cash Return on Invested Capital (CROIC)	0.00%	-1,413.30%	-1,096.96%	-556.10%	-400.20%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	-42.63%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	-37.91%
Return on Common Equity (ROCE)	0.00%	-204.87%	112.04%	74.19%	109.01%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-204.87%	13.51%	12.28%	16.42%
Net Operating Profit after Tax (NOPAT)	-19	-39	-107	-106	-129
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-169,175.26%
Net Nonoperating Expense Percent (NNEP)	0.00%	-161.19%	-16.06%	-6.89%	-9.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	9.77%	9.61%	12.92%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	73,794.74%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	167,984.21%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	241,778.95%
Earnings before Interest and Taxes (EBIT)	-27	-55	-153	-152	-184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-26	-53	-150	-148	-178
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	6,485.64
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	184.38	54.62	35.33
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	20,147.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.76	-0.96	-0.95	-0.91
Leverage Ratio	0.00	1.50	1.05	1.05	1.09
Compound Leverage Factor	0.00	1.50	1.01	0.89	0.97
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	317.18%	381.96%	347.72%
Common Equity to Total Capital	0.00%	100.00%	-217.18%	-281.96%	-247.72%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	70.56	4.61	3.29
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	301.13%	345.46%	364.62%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	2.21	46.42	14.94	10.93
Quick Ratio	0.00	1.67	45.09	14.50	9.89
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-45	-115	-120	-144
Operating Cash Flow to CapEx	-461.53%	-968.97%	-4,176.00%	-263.38%	-428.18%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-536.90	-9,980.37	-15,948.02
Operating Cash Flow to Interest Expense	0.00	0.00	-358.55	-7,505.75	-14,039.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-367.14	-10,355.50	-17,317.78
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	6.36	15	28	43
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	6.36	8.33	14	15
Enterprise Value (EV)	0.00	0.00	2,708	1,551	1,531
Market Capitalization	200	0.00	1,597	419	493
Book Value per Share	$0.00	$0.84	($4.71)	($4.69)	($3.41)
Tangible Book Value per Share	$0.00	$0.83	($4.71)	($4.69)	($3.41)
Total Capital	0.00	27	505	391	402
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-21	-490	-363	-358
Capital Expenditures (CapEx)	5.46	5.19	1.85	34	30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-5.60	3.59	-14	1.38
Debt-free Net Working Capital (DFNWC)	0.00	15	494	349	360
Net Working Capital (NWC)	0.00	15	494	349	360
Net Nonoperating Expense (NNE)	7.83	17	41	29	35
Net Nonoperating Obligations (NNO)	0.00	-21	-490	-363	-358
Total Depreciation and Amortization (D&A)	0.96	1.98	3.04	3.85	5.43
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	1,809.21%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	473,246.05%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	473,246.05%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.23)	($0.57)	($0.62)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	61.54M	61.71M	97.92M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.23)	($0.57)	($0.62)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	61.54M	61.71M	97.92M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	234.92M	229.34M	292.70M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-39	-107	-106	-129
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-169,175.26%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	-215,701.32%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-711.66	-12,626.83	-20,408.44
NOPAT to Interest Expense	0.00	0.00	-498.16	-8,838.78	-14,285.91
EBIT Less CapEx to Interest Expense	0.00	0.00	-720.25	-15,476.58	-23,687.22
NOPAT Less CapEx to Interest Expense	0.00	0.00	-506.75	-11,688.53	-17,564.69
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-7.01%	0.00%

This table displays calculated financial ratios and metrics derived from ProKidney's official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	39.10%	-94.88%	-31.11%	21.67%	2.67%	-7.28%	-4.11%	-116.78%	-2.09%	8.48%	22.37%
EBIT Growth	38.50%	-92.01%	-31.05%	19.93%	1.96%	-8.13%	-5.05%	-113.02%	-3.27%	7.77%	21.31%
NOPAT Growth	38.50%	-92.01%	-31.05%	19.93%	1.96%	-8.13%	-5.05%	-113.02%	-3.27%	7.77%	21.31%
Net Income Growth	45.31%	-57.35%	-23.70%	11.59%	4.27%	-10.46%	2.23%	-123.18%	-7.41%	3.90%	12.69%
EPS Growth	0.00%	0.00%	-38.46%	10.00%	0.00%	-14.29%	22.22%	-77.78%	18.75%	18.75%	14.29%
Operating Cash Flow Growth	-68.14%	35.22%	-4.09%	-61.06%	-33.29%	-156.72%	-22.98%	4.78%	14.59%	17.96%	9.05%
Free Cash Flow Firm Growth	0.00%	178.63%	-107.94%	0.00%	-125.92%	-130.60%	-325.51%	-66.61%	31.39%	47.33%	43.36%
Invested Capital Growth	-92.72%	-95.40%	0.00%	93.27%	124.87%	277.54%	0.00%	52.70%	13.10%	9.53%	36.02%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	202.63%	-3.91%	-1.81%
EBITDA Q/Q Growth	-36.00%	2.73%	-17.11%	49.43%	-68.98%	-7.22%	-13.64%	-5.29%	20.42%	3.88%	3.60%
EBIT Q/Q Growth	-35.19%	2.59%	-17.07%	48.07%	-65.53%	-7.44%	-13.74%	-5.31%	19.75%	4.06%	2.95%
NOPAT Q/Q Growth	-35.19%	2.59%	-17.07%	48.07%	-65.53%	-7.44%	-13.74%	-5.31%	19.75%	4.06%	2.95%
Net Income Q/Q Growth	-50.20%	5.65%	-20.58%	48.27%	-62.65%	-8.87%	-6.73%	-18.10%	21.72%	2.60%	3.04%
EPS Q/Q Growth	-60.00%	12.50%	-28.57%	50.00%	-77.78%	0.00%	12.50%	-14.29%	18.75%	0.00%	7.69%
Operating Cash Flow Q/Q Growth	-64.91%	42.61%	-59.41%	-6.76%	-36.49%	-10.53%	23.64%	17.34%	-22.43%	-6.16%	15.34%
Free Cash Flow Firm Q/Q Growth	0.00%	2.62%	-108.48%	-83.83%	-62.02%	-21.16%	-17.92%	28.02%	33.28%	6.99%	-26.80%
Invested Capital Q/Q Growth	17.77%	-37.47%	-100.00%	0.00%	37.03%	4.99%	-10.23%	18.25%	1.49%	1.67%	11.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-65,785.53%	-17,299.13%	-17,304.98%	-16,988.94%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-67,856.58%	-17,994.78%	-17,967.87%	-17,759.91%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-67,856.58%	-17,994.78%	-17,967.87%	-17,759.91%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-63,793.42%	-16,500.87%	-16,726.24%	-16,517.51%
Tax Burden Percent	103.73%	102.85%	102.22%	114.74%	100.28%	99.85%	94.60%	103.64%	101.58%	102.35%	101.59%
Interest Burden Percent	87.05%	85.03%	88.12%	78.20%	87.92%	89.47%	88.61%	90.71%	90.27%	90.95%	91.55%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.65%	-93.01%	-154.94%	-213.82%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-97.22%	-90.24%	-152.42%	-211.20%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	88.42%	80.04%	136.35%	187.21%
Return on Equity (ROE)	-32.72%	-37.63%	0.00%	-30.22%	-31.72%	-29.59%	-30.80%	-12.23%	-12.97%	-18.59%	-26.61%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-556.10%	-452.39%	-533.54%	-797.01%	-400.20%	-324.75%	-306.31%	-307.57%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-11.97%	-13.87%	-21.74%	-31.98%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-11.25%	-12.72%	-20.23%	-29.74%
Return on Common Equity (ROCE)	73.48%	72.68%	0.00%	74.19%	101.39%	73.07%	68.04%	32.36%	37.05%	45.22%	69.43%
Return on Equity Simple (ROE_SIMPLE)	7.34%	9.85%	0.00%	0.00%	12.21%	14.14%	13.94%	0.00%	16.62%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-29	-28	-33	-17	-28	-30	-34	-36	-29	-28	-27
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-47,499.61%	-12,596.35%	-12,577.51%	-12,431.94%
Net Nonoperating Expense Percent (NNEP)	-3.58%	-3.11%	0.00%	-1.12%	-1.85%	-1.90%	-3.33%	-3.43%	-2.76%	-2.52%	-2.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	1.54%	2.57%	-	-	3.63%	2.91%	2.77%	2.68%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	15,613.16%	6,241.30%	6,356.56%	5,500.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	52,343.42%	11,853.48%	11,711.31%	12,359.91%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	67,956.58%	18,094.78%	18,067.87%	17,859.91%
Earnings before Interest and Taxes (EBIT)	-41	-40	-47	-24	-40	-43	-49	-52	-41	-40	-39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-39	-46	-23	-39	-42	-47	-50	-40	-38	-37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6,485.64	838.11	328.86	957.21
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	19.60	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	5.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	247.33	366.51	0.00	54.62	38.85	38.77	42.90	35.33	29.53	27.29	35.50
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20,147.47	4,245.12	2,316.00	2,379.09
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.00	0.01
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.00	0.01
Financial Leverage	-0.65	-0.64	0.00	-0.95	-0.93	-0.94	-0.92	-0.91	-0.89	-0.89	-0.89
Leverage Ratio	1.04	1.06	0.00	1.05	1.05	1.06	1.07	1.09	1.08	1.07	1.08
Compound Leverage Factor	0.90	0.90	0.00	0.82	0.92	0.95	0.95	0.99	0.98	0.98	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	1.32%	0.00%	0.00%	0.00%	0.67%	0.00%	1.01%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	1.32%	0.00%	0.00%	0.00%	0.67%	0.00%	1.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	432.97%	389.37%	0.00%	381.96%	396.61%	305.85%	320.92%	347.72%	367.40%	395.33%	412.45%
Common Equity to Total Capital	-332.97%	-289.37%	0.00%	-281.96%	-297.93%	-205.85%	-220.92%	-247.72%	-268.08%	-295.33%	-313.46%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.03	0.00	0.00	0.00	-0.01	0.00	-0.02
Net Debt to EBITDA	0.00	0.00	0.00	0.00	2.21	0.00	0.00	0.00	1.82	0.00	1.63
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.03	0.00	0.00	0.00	-0.01	0.00	-0.02
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.05	0.00	0.00	0.00	-0.02	0.00	-0.03
Net Debt to NOPAT	0.00	0.00	0.00	0.00	3.07	0.00	0.00	0.00	2.52	0.00	2.24
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.05	0.00	0.00	0.00	-0.02	0.00	-0.03
Altman Z-Score	108.85	54.79	0.00	5.61	5.63	10.25	7.86	4.28	0.70	-0.86	8.43
Noncontrolling Interest Sharing Ratio	324.58%	293.16%	0.00%	345.46%	419.61%	346.92%	320.92%	364.62%	385.75%	343.26%	360.92%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	42.57	19.04	0.00	14.94	17.62	21.87	17.09	10.93	10.96	11.48	10.32
Quick Ratio	41.11	18.21	0.00	14.50	17.05	20.96	16.16	9.89	10.01	10.43	9.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	192	197	-17	-31	-50	-60	-71	-51	-34	-32	-40
Operating Cash Flow to CapEx	-2,636.11%	-403.14%	-85.10%	-1,614.76%	-3,608.96%	-6,020.91%	-1,216.35%	-94.75%	-2,607.22%	-1,009.51%	-511.76%
Free Cash Flow to Firm to Interest Expense	63,851.28	49,143.21	-8,335.45	-10,215.33	-24,826.10	-20,052.73	-35,468.55	-25,529.35	0.00	-31,686.30	-20,089.65
Operating Cash Flow to Interest Expense	-8,664.00	-3,729.00	-11,888.50	-8,461.33	-17,323.00	-12,764.33	-14,620.50	-12,085.50	0.00	-31,416.00	-13,298.00
Operating Cash Flow Less CapEx to Interest Expense	-8,992.67	-4,654.00	-25,858.00	-8,985.33	-17,803.00	-12,976.33	-15,822.50	-24,840.00	0.00	-34,528.00	-15,896.50
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.02
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	17	11	0.00	28	39	41	37	43	44	45	50
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.02
Increase / (Decrease) in Invested Capital	-220	-224	-16	14	22	30	37	15	5.10	3.89	13
Enterprise Value (EV)	4,278	3,964	0.00	1,551	1,511	1,583	1,573	1,531	1,299	1,221	1,770
Market Capitalization	2,659	2,631	1,077	419	376	570	556	493	256	173	712
Book Value per Share	($6.82)	($5.62)	$0.00	($4.69)	($4.78)	($4.20)	($3.38)	($3.41)	($3.41)	($3.43)	($3.43)
Tangible Book Value per Share	($6.82)	($5.62)	$0.00	($4.69)	($4.78)	($4.20)	($3.38)	($3.41)	($3.41)	($3.43)	($3.43)
Total Capital	481	457	0.00	391	368	472	443	402	372	339	322
Total Debt	0.00	0.00	0.00	0.00	4.86	0.00	0.00	0.00	2.51	0.00	3.25
Total Long-Term Debt	0.00	0.00	0.00	0.00	4.86	0.00	0.00	0.00	2.51	0.00	3.25
Net Debt	-464	-446	0.00	-363	-324	-432	-407	-358	-326	-295	-268
Capital Expenditures (CapEx)	0.99	3.70	28	1.57	0.96	0.64	2.40	26	1.14	3.11	5.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	5.18	-4.19	0.00	-14	-8.14	-1.86	-1.77	1.38	-1.64	1.45	-0.80
Debt-free Net Working Capital (DFNWC)	469	442	0.00	349	321	430	405	360	327	296	271
Net Working Capital (NWC)	469	442	0.00	349	321	430	405	360	327	296	271
Net Nonoperating Expense (NNE)	8.30	6.95	9.36	4.78	7.28	8.33	6.77	12	8.98	9.17	8.87
Net Nonoperating Obligations (NNO)	-464	-446	0.00	-363	-324	-432	-407	-358	-326	-295	-268
Total Depreciation and Amortization (D&A)	0.83	0.87	1.01	1.15	1.10	1.27	1.49	1.57	1.60	1.47	1.67
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,809.21%	-537.25%	275.14%	-107.39%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	473,246.05%	106,815.03%	56,200.76%	36,414.78%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	473,246.05%	106,815.03%	56,200.76%	36,414.78%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	($0.14)	$0.00	($0.09)	($0.16)	($0.16)	($0.14)	($0.16)	($0.13)	($0.13)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	61.54M	64.56M	0.00	61.71M	60.95M	75.91M	126.17M	97.92M	128.98M	130.73M	134.99M
Adjusted Diluted Earnings per Share	($0.16)	($0.14)	$0.00	($0.09)	($0.16)	($0.16)	($0.14)	($0.16)	($0.13)	($0.13)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	61.54M	64.56M	0.00	61.71M	60.95M	75.91M	126.17M	97.92M	128.98M	130.73M	134.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	235.13M	235.25M	0.00	229.34M	231.70M	289.68M	291.66M	292.70M	292.70M	294.28M	300.83M
Normalized Net Operating Profit after Tax (NOPAT)	-29	-28	-33	-17	-28	-30	-34	-36	-29	-28	-27
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-47,499.61%	-12,596.35%	-12,577.51%	-12,431.94%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-61,553.95%	-16,243.91%	-16,342.53%	-16,259.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-13,625.33	-9,954.75	-23,308.50	-8,070.00	-20,038.00	-14,352.00	-24,486.50	-25,785.50	0.00	-39,709.00	-19,269.50
NOPAT to Interest Expense	-9,537.73	-6,968.33	-16,315.95	-5,649.00	-14,026.60	-10,046.40	-17,140.55	-18,049.85	0.00	-27,796.30	-13,488.65
EBIT Less CapEx to Interest Expense	-13,954.00	-10,879.75	-37,278.00	-8,594.00	-20,518.00	-14,564.00	-25,688.50	-38,540.00	0.00	-42,821.00	-21,868.00
NOPAT Less CapEx to Interest Expense	-9,866.40	-7,893.33	-30,285.45	-6,173.00	-14,506.60	-10,258.40	-18,342.55	-30,804.35	0.00	-30,908.30	-16,087.15
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-7.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key four-year (2022–2025) trends for PROKIDNEY CORP. (NASDAQ: PROK) based on quarterly cash flow statements, income statements, and balance sheets. The company remains in an early-stage, cash-burn mode with limited revenue, but maintains sizable liquidity and occasional investment-driven cash inflows that help extend runway.

Strong liquidity runway as of Q3 2025: cash and short-term investments total about $271.7 million (Cash ~ $95.3M + Short-Term Investments ~ $176.4M), providing substantial liquidity to fund ongoing R&D and operations.
First signs of revenue in 2025: operating revenue in Q3 2025 was $0.217 million, with Q1 2025 at about $0.230 million, indicating limited but real monetization beginning.
Investing activity adds liquidity in 2025: net cash from investing activities delivered multi-million inflows in 2025 (Q3 +$29.0M, Q2 +$18.6M, Q1 +$28.3M from maturities/sales of investments), supplementing operating cash burn.
Ongoing cash burn from operations: net cash from operating activities remains negative across recent quarters (e.g., CFO: Q3 2025 about -$26.6M, Q2 2025 about -$31.4M, Q1 2025 about -$29.6M), signaling continued reliance on external funding.
Very large redeemable noncontrolling interest on the balance sheet: Redeemable Noncontrolling Interest runs around $1.32B–$1.34B, creating substantial minority claims and potential equity dilution considerations for common shareholders.
Persistent losses and negative EPS: Q3 2025 net income from continuing operations was -$35.8 million with diluted EPS of -$0.12, underscoring ongoing profitability challenges despite tiny revenue.
Negative shareholder equity dynamics: substantial accumulated deficits and negative Retained Earnings (e.g., Retained Earnings around -$1.25B in Q3 2025; Total Common Equity and Total Equity also materially negative), suggesting meaningful dilution risk and balance-sheet fragility.

05/16/26 06:41 PM ETAI Generated. May Contain Errors.

ProKidney Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ProKidney's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

ProKidney's net income appears to be on an upward trend, with a most recent value of -$163.34 million in 2024, rising from -$26.75 million in 2020. The previous period was -$135.45 million in 2023. Check out ProKidney's forecast to explore projected trends and price targets.

ProKidney's total operating income in 2024 was -$183.68 million, based on the following breakdown:

Total Gross Profit: $76 thousand
Total Operating Expenses: $183.75 million

Over the last 4 years, ProKidney's total revenue changed from $0.00 in 2020 to $76 thousand in 2024, a change of 7,600,000.0%.

ProKidney's total liabilities were at $39.44 million at the end of 2024, a 35.0% increase from 2023, and a 194.7% increase since 2021.

In the past 3 years, ProKidney's cash and equivalents has ranged from $20.56 million in 2021 to $490.25 million in 2022, and is currently $99.12 million as of their latest financial filing in 2024.

Over the last 4 years, ProKidney's book value per share changed from 0.00 in 2020 to -3.41 in 2024, a change of -341.1%.

Related Companies

Financial statements for NASDAQ:PROK last updated on 11/14/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Financials

Financials Breakdown Chart

Key Financial Trends

ProKidney Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Financials

Annual Income Statements for ProKidney

Quarterly Income Statements for ProKidney

Annual Cash Flow Statements for ProKidney

Quarterly Cash Flow Statements for ProKidney

Annual Balance Sheets for ProKidney

Quarterly Balance Sheets for ProKidney

Annual Metrics And Ratios for ProKidney

Quarterly Metrics And Ratios for ProKidney

Financials Breakdown Chart

Key Financial Trends

ProKidney Financials - Frequently Asked Questions

When does ProKidney's financial year end?

How has ProKidney's net income changed over the last 4 years?

What is ProKidney's operating income?

How has ProKidney's revenue changed over the last 4 years?

How much debt does ProKidney have?

How much cash does ProKidney have?

How has ProKidney's book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools